What is OpenEvidence?
OpenEvidence operates as a specialized medical information platform, originally incubated within the Mayo Clinic Platform Accelerate program. The company provides healthcare professionals with unlimited, high-fidelity access to medical data, a mission that has earned it significant validation from the New England Journal of Medicine AI. By leveraging advanced artificial intelligence, OpenEvidence addresses the critical need for synthesized, evidence-based insights in clinical settings, positioning itself as an essential utility for practitioners across the United States. The platform's commitment to free access for medical professionals has fostered a robust user base, establishing it as a leader in the digital health information landscape.
How much funding has OpenEvidence raised?
OpenEvidence has raised a total of $880M across 5 funding rounds:
Seed
$20M
Multiple Rounds
$610M
Series D
$250M
Seed (2021): $20M, investors not publicly disclosed
Series B (2025): $210M led by Kleiner Perkins, Thrive, Conviction, Coatue, Google, and Sequoia Capital
Other Financing Round (2025): $200M supported by Blackstone, Thrive Capital, Sequoia Capital, Kleiner Perkins, Google, and Coatue
Series C (2025): $200M featuring Sequoia Capital, GV, Thrive Capital, and Kleiner Perkins
Series D (2026): $250M backed by Thrive Capital and DST Global
Key Investors in OpenEvidence
Thrive Capital
Thrive Capital is a New York-based venture capital firm that specializes in internet and software investments, providing strategic support to high-growth technology companies.
Sequoia Capital
Sequoia Capital is a globally recognized venture firm with an unparalleled track record of partnering with entrepreneurs to build market-leading companies across various technology sectors.
Kleiner Perkins
Kleiner Perkins is a Menlo Park-based firm that invests in early and growth-stage technology and life science companies, offering operational support from seed through IPO.
What's next for OpenEvidence?
With the successful closure of its latest funding round, OpenEvidence is poised to accelerate its product development roadmap and expand its reach within the global healthcare ecosystem. The strategic capital will likely be deployed toward enhancing the platform's AI capabilities, broadening its database of clinical evidence, and scaling infrastructure to support a larger user base. As the company transitions from its initial growth phase into a more mature enterprise-level operation, the focus will remain on maintaining the integrity of its medical information while exploring new avenues for institutional integration and clinical decision support. The continued support from top-tier investors suggests a strong confidence in the company's long-term potential to redefine how medical knowledge is accessed and utilized.
See full OpenEvidence company page
